Skip to main content
CLVLF logo

Clinuvel Pharmaceuticals Limited (CLVLF) Stock Price & Analysis

Clinuvel Pharmaceuticals Limited (CLVLF) — price $4.95 (0.00%), as of the Nov 19, 2026 trading session; market cap $250M.

Educational signal · not a buy or sell recommendation · How to read this

$4.95 $0.00 (0.00%) Market Cap $250M

Clinuvel Pharmaceuticals Limited · CLVLF

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing treatments for genetic, metabolic, and life-threatening disorders. Its lead drug, SCENESSE, addresses phototoxicity in erythropoietic protoporphyria (EPP) patients, with a pipeline targeting neurological and dermatological conditions.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • PLX · Protalix BioTherapeutics, Inc. · 90 /100
  • CGEN · Compugen Ltd. · 69 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$4.95
Change on the day0.00%
52-week range$4.95 – $8.45
Market capitalisation$250M
Price / earnings (trailing)10.68
Shares traded on the day300

Price & events

Other perspectives

Council score for Clinuvel Pharmaceuticals (CLVLF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Strong
Revenue Growth Neutral
Debt/Equity Moderate
ROE Moderate
Gross Margin Strong

Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Clinuvel Pharmaceuticals (CLVLF), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Clinuvel Pharmaceuticals Limited (CLVLF) is the company analyzed here. It employs 109 people and is led by Philippe Jacques Wolgen. In Q4 FY2026 it reported revenue of A$57M and net income of A$23M. The market values it at $250M.

2 · Latest results

What do the latest results show for Clinuvel Pharmaceuticals (CLVLF)?

Short answer · as of

The most recent reported quarter, Q4 FY2026, carried revenue of A$57M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2026A$57MA$23MA$0.47 (diluted)
Q2 FY2026A$37MA$10MA$0.21 (diluted)
Q4 FY2025A$59MA$22MA$0.44 (diluted)
Q2 FY2025A$36MA$14MA$0.28 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Clinuvel Pharmaceuticals (CLVLF)?

Short answer · as of

The distress and quality screens read Altman Z 11.89 · Piotroski F 7. Trailing ratios: ROE 13.0% · ROA 11.5% · current ratio 14.81 · earnings yield 9.0% · free-cash-flow yield 9.2%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CLVLF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CLVLF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Clinuvel Pharmaceuticals (CLVLF)

These answers are editorial: 1 of these 8 answers is drawn from the CLVLF research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is CLVLF a good stock to buy?

Stock Expert AI does not rate CLVLF buy, sell or hold. Clinuvel Pharmaceuticals Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CLVLF stock price today?

The last price recorded for Clinuvel Pharmaceuticals Limited (CLVLF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about CLVLF stock?

Analyst coverage of CLVLF is limited due to its OTC listing and smaller market capitalization. However, the company's strong gross and profit margins, coupled with its focus on a niche market, are viewed positively.

What are the key factors to evaluate for CLVLF?

Evaluate CLVLF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. SCENESSE is approved for erythropoietic protoporphyria (EPP) in Europe and the United States, addressing a significant unmet need for photoprotection. Not financial advice.

How frequently does CLVLF data refresh on this page?

CLVLF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CLVLF's recent stock price performance?

Clinuvel Pharmaceuticals Limited (CLVLF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary melanocortin technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CLVLF overvalued or undervalued right now?

The trailing P/E of Clinuvel Pharmaceuticals Limited (CLVLF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research CLVLF before investing?

Before investing in Clinuvel Pharmaceuticals Limited (CLVLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 15 figures on this page — 9 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.